Fund moves
7.6%Stake
A Schedule 13D means the holder owns more than 5% and keeps the option to push for changes: board seats, a sale, buybacks. It must be filed within 5 business days.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
AUTL · NASDAQ · Biological Products, (No Diagnostic Substances)
Autolus Therapeutics (AUTL) · oqro.io/stocks/AUTL · printed today. Every figure comes from a public filing, linked on the page online. Not investment advice.
No open-market purchase by an insider of Autolus Therapeutics is on record in SEC filings since 2006.
Since 2026, Autolus Therapeutics insiders reported 0 open-market purchases and 1 sale on Forms 4 and 5.
In the last 90 days, 1 insider of Autolus Therapeutics (AUTL) reported 1 open-market sale worth $16K in total on SEC Form 4. The largest seller by value was Cintia Piccina, with $16K. Many insider sales follow a plan set in advance or cover taxes on stock awards; the filing says what was sold, not the reason.
No trade in Autolus Therapeutics (AUTL) was disclosed by a member of Congress in the last 12 months.
From official filings only: SEC Forms 4, 5 and 144 for insiders, House and Senate periodic transaction reports for Congress, SEC Form 13F for funds, Form 8-K for company events and USAspending for federal contracts. Every record on OQRO links to its source. It is public data, not investment advice.
$0.9073−0.0723 (−7.38%)
Close of Nov 20, 2026, vs Nov 19 · end-of-day
−26.2% (−$0.3227) from Nov 20, 2025 to Nov 20, 2026 · adjusted daily closes
Adjusted close went from $1.23 on Nov 20, 2025 to $0.9073 on Nov 20, 2026 (−26.2%). Disclosed in this range: 1 insider trade, 0 pre-arranged insider sales, 0 Congress trades, and 1 13F position change for 1 quarter ending in it.
Counts of filings OQRO holds, by the date each was filed or the award started. Every figure links to its official SEC, House, Senate or USAspending record.
Biological Products, (No Diagnostic Substances) company based in London, X0.
Last 12 months
−26.2%
Market value
$290M
S&P 500 +5.7% over the same dates. Prices adjusted for splits and dividends.
Short interest: 8.63M shares sold short (2.7% of shares outstanding), −4.8% vs the previous count, 4.7 days of normal trading to buy them back. FINRA, as of Oct 30, 2026. Short interest history
Revenue, fiscal 2025
$75.4M
Year ended Dec 31, 2025
Net income, fiscal 2025
−$288M
A loss for the year
Shares outstanding
266M
As of Nov 9, 2026
Fund moves
A Schedule 13D means the holder owns more than 5% and keeps the option to push for changes: board seats, a sale, buybacks. It must be filed within 5 business days.
Fund moves
From a 13F filed Nov 6, 2026 covering holdings at Sep 30, 2026 — a quarter-end snapshot, not a live trade.
Insider selling
Traded Sep 2 · filed 1 day laterNot reported under a pre-arranged trading plan
Since the trade −59.5% · S&P 500 −9.8% · to Nov 20
Autolus Therapeutics's U.S. CCO & Country Gen Manager sold $16K of Autolus Therapeutics shares. The filing does not indicate a pre-arranged trading plan.
Fund moves
4 tracked managers disclosed the same change for Q3 2025. From a 13F filed Nov 14, 2025 covering holdings at Sep 30, 2025 — a quarter-end snapshot, not a live trade.
Fund moves
2 tracked managers disclosed the same change for Q2 2025. From a 13F filed Aug 14, 2025 covering holdings at Jun 30, 2025 — a quarter-end snapshot, not a live trade.
Prices are daily closes from Polygon.io. Company figures come from its own SEC filings. Past moves are not a forecast. OQRO reports what was filed and never tells you what to buy or sell.
Insiders of Autolus Therapeutics reported 0 open-market purchases and 1 sale since 2026; no open-market purchase.
| Year | Bought | Sold |
|---|---|---|
| 2026 | — | $16K1×1 trade |
Open-market purchases (code P) and sales (code S) on Forms 4 and 5. Up to Sep 2024 from the SEC's Insider Transactions Data Sets; since Oct 2024 from each filing as it is published. A trade filed twice (an amendment) counts once. Dollar totals use the price the filer reported; lines with no price count as trades without a value.
Changed auditor
8-K on sec.govTop officer leaving
“Dolski notified the Company of his intention to resign as principal accounting officer of the Company;”
8-K on sec.govFrom the company's 8-K, 10-K and 10-Q filings over the last two years. A flag is a reason to read the filing, not a verdict: many departures are planned retirements and many listing notices are resolved. Insider sales are shown for timing only; they are separate filings.
BXLS V - Autobahn L.P.
13D · may seek influence · Amended · 20.5M shares · filed Nov 10, 2026
MAK Capital Fund LP
13G · passive · Amended · 30.5M shares · filed Nov 16, 2026
Armistice Capital, LLC
13G · passive · Amended · 13.8M shares · filed Nov 16, 2026
Source: SEC Schedules 13D and 13G, which anyone owning more than 5% of a class of stock must file. A 13D filer may seek to influence the company; a 13G filer is passive. Filings before December 2024 are free text and read from their cover page: a percent or share count that is not stated plainly is left blank. Each line links to the filing.
Against the S&P 500 over the year
Since Nov 18, 2025, AUTL is down 29.7% and the index fund is up 4.5%: 34 points behind the market. Traders call a stock that beats the index over a period a relative-strength leader.
How much AUTL moves
Beta 1.8 (1 year vs SPY)
End-of-day prices. These figures describe the past year and say nothing about what comes next. Beta: how much the stock moved, on average, for each 1% move of the S&P 500 fund over 249 trading days (1 = in step with it).
Written by OQRO's software from the last 12 months on record · Nov 19, 2026
Every number, name, date and link in the text above comes from this list; software checks that before the text is stored. This text was assembled directly from the facts, without a language model.
Insiders
Funds and stakes
Contracts, lobbying and filings
Company reports, price and press
Who holds it
Things to keep in mind
Revenue
$41.2M
+94.6% vs the same quarter a year earlier
Free cash flow, last 12 months
−$180M
This quarter −$19.8M, a year earlier −$72.3M
Net debt
—
Debt —, cash $245M, at Sep 30, 2026
Net income, last 12 months
−$256M
Operating loss: profit did not cover interest
From the company's own quarterly and annual reports to the SEC. Free cash flow (cash from operations minus capital spending), net debt (debt minus cash) and 12-month totals are calculated by OQRO. Production rates, deliveries, approvals and guidance are in its results announcement of Nov 10, 2026.
Revenue and earnings history, 10 fiscal yearsEarnings dates and the stock's moves
Latest annual report filed Mar 27, 2026, compared with the one filed Mar 20, 2025. Read the filing
None reported.
Source: SEC EDGAR, Form 10-K filed Mar 27, 2026. Headings are the titles the company gives each risk; OQRO compares them with the year before by their words, so a heading that was reworded a lot shows up as both new and no longer listed. Companies list the risks they face, not forecasts.
The three months Jul 1, 2026 to Sep 30, 2026, compared with the same quarter a year earlier, from the quarterly report filed Nov 10, 2026. Quarterly reports are not audited. Read the filing
+95% on the same quarter a year earlier ($21.1M)
$50K the same quarter a year earlier
Fiscal year Jan 1, 2025 to Dec 31, 2025, from the annual report filed Mar 27, 2026. Read the filing
$0 the year before
−89% on the year before ($10.1M)
Every annual report has a section where the company's managers explain the year's results (Item 7, Management's discussion and analysis). In this report it runs to about 12,000 words.
We are an early commercial-stage biopharmaceutical company developing next-generation programmed T cell therapies for the treatment of cancer and autoimmune diseases. Using our broad suite of proprietary and modular T cell programming technologies, we are engineering precisely targeted, controlled and highly active T cell therapies that are designed to better recognize target cells, break down their defense mechanisms and attack and kill these cells. We believe our programmed T cell therapies have the potential to be best-in-class and to offer patients substantial benefits over the existing standard of care, including the potential for cure in some patients. Since our inception, we have incurred significant operating losses.
Source: SEC EDGAR, Form 10-K filed Mar 27, 2026 and Form 10-Q filed Nov 10, 2026. Revenue lines are the figures the company tags in its filing; OQRO shows a split only when its lines add up to the reported total revenue. The quote is the opening of the managers' discussion, cut at a sentence; the word count is estimated from its length. Not investment advice.
And 26 more headings in the filing.
Off-exchange trading: 51.4% of the shares traded over the latest 4 published weeks changed hands away from the exchanges (20.7% on ATS, 30.7% with other brokers), close to its 26-week average of 49.7%. Weeks of Sep 21 to Oct 16, 2026.
Largest ATS: MS POOL (ATS-4) (16.1%), INTELLIGENT CROSS LLC (13.7%), INSTINCT X (10.8%), as a share of this stock's ATS volume over the same 4 weeks.
An ATS, often called a dark pool, is a private trading venue run by a broker where orders are not shown publicly before they trade. Other off-exchange trades are mostly retail orders filled by wholesale brokers. A high share is common and says nothing by itself about where the price goes. FINRA OTC Transparency data, published 2 weeks after each week for the largest stocks and 4 weeks for others; total volume from our daily price data.